MRMark Rosenberg

Mark Rosenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark Rosenberg has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of vessel diameter on the clinical benefits of drug-coated balloon angioplasty: Insights from paclitaxel-coated balloon and polymer-free sirolimus-eluting stent studies

    by Florian Krackhardt, Klaus Bonaventura, Matthias Waliszewski, Mark Rosenberg, Monica Verdoia, Uwe Zeymer, Rene Koning, Quentin Landolff

    Background: 20 years ago, drug coated balloon (DCB) angioplasty was introduced into the interventionalist’s toolbox initially to treat in-stent restenosis. Since then, considerable clinical evidence was generated in patients with de novo lesions. Whether drug-eluting stents (DES) or DCB angioplasty are associated with better clinical outcomes for de novo lesion treatment is still a matter of debate. Objective: The objective of this post-hoc analysis was to assess the impact of vessel diameter in a real-world, unselected patient population treated with either paclitaxel-coated balloon (PCB) angioplasty or polymer-free sirolimus-eluting stent (PF-SES) implantation based on patient-level data. Methods: Four all-comers observational studies based on similar protocols were pooled and vessel-diameter matched to study the clinical outcomes following revascularization with either PCB or PF-SES. The primary endpoint in all studies was the accumulated clinically driven target lesion revascularization (TLR) rate at 9–12 months complemented with secondary endpoints such as the rates for major adverse cardiac events (MACE), myocardial infarction (MI) and cardiac death. Results: In the unmatched patient population, 3035 patients received either PCB (1614 patients) or PF-SES (1421 patients). The ‘unmatched’ TLR and MACE rates were low with 2.5% (PCB) vs. 2.0% (PF-SES, p = 0.319) and 4.5% (PCB) vs. 5.0% (PF-SES, p = 0.493), respectively. In the large vessel group (≥ 3 mm), 253 patient pairs were matched with reference diameters of 3.19 ± 0.27 mm (PCB) and 3.18 ± 0.27 mm (PF-SES, p = 0.787), and lesion lengths of 17.5 ± 9.8 mm (PCB) and 17.3 ± 7.1 mm (PF-SES, p = 0.839). The accumulated TLR rates were not significantly different (PCB 2.0% vs. PF-SES 2.8%, p = 0.786). Likewise, MACE rates in this large vessel subgroup were similar (5.6% vs. 6.4%, p = 0.723). In the small vessel group (< 3 mm), 420 patient pairs were matched with reference diameters of 2.49 ± 0.18 mm (PCB) and 2.49 ± 0.18 mm (PF-SES, p = .995), and lesion lengths of 16.0 ± 9.0 mm (PCB) and 16.7 ± 7.1 mm (PF-SES, p = 0.665). The accumulated TLR rates were not significantly different (PCB 1.9% vs. PF-SES 2.2%, p = 0.810). Likewise, MACE rates in the small vessel subgroup were similar (4.4% vs. 5.8%, p = 0.346). Individual clinical event rates were low and not significantly different between patients with small and large vessels. Conclusions: In this real-world experience PCB and PF-SES angioplasty were associated with low clinical event rates. There was no difference in clinical efficacy between PCB and PF-SES in large and small vessel PCI in terms of clinically driven TLR and MACE. Previously reported higher rates for clinical events after DCB angioplasty in large coronary vessels ≥ 3 mm could not be observed. Graphical


  • Haemodynamics of an iatrogenic atrial septal defect after MitraClip implantation

    by Matthias Eden, Leonhard Leeb, Norbert Frey, Mark Rosenberg

    Background: The MitraClip procedure requires transseptal access of the left atrium with a 24F guiding sheath. We evaluated invasively whether a MitraClip induced iatrogenic atrial septal defect (IASD) leads to development of a relevant interatrial shunt and right ventricular overload.Methods: A total of 69 patients who underwent a MitraClip procedure due to a severe mitral valve regurgitation (MVR) were included in the observational, retrospective cohort study. All pressures were directly measured throughout the procedure. Cardiac index (CI), systemic (Qs) and pulmonary (Qp) flow were calculated using the Fick method.Results: Successful MitraClip implantation increased CI (2.5 ± 0.62 vs 3.05 ± 0.77 L/min/m2; P < .0001), whereas SVR (1491 ± 474 vs 997 ± 301 dyn s/cm5; P < .0001), PVR (226 ± 121 vs 188 ± 96 dyn/s/cm5; P = .04), PCWP (23 ± 6.1 vs 20 ± 4.7 mm Hg; P = .0031), PA pressure (33.6 ± 7.2 vs 31.9 ± 6.6 mm Hg; P = .1437) and LA pressure (21.5 ± 5.4 vs 18.7 ± 4.9 mm Hg; P < .0001) all decreased. The effect on LA pressure was further enhanced by guiding catheter retrieval (14.4 ± 4.6 mm Hg; P < .0001). At the end of the procedure, Qp (6.033 ± 1.3 L/min) exceeded Qs (5.537 ± 1.3 L/min) by 0.496 L/min leading to a Qp:Qs ratio of 1.09 (P = .007). After 6 months, echocardiography revealed no changes in RV diameter (42.96 ± 6.95 mm vs 43.81 ± 7.67 mm; P = .62) and TAPSE (17.13 ± 3.33 mm vs 17.36 ± 3.24 mm; P = .48).Conclusion: Our data show that the MitraClip procedure does not induce a relevant interatrial shunt or right ventricular overload. In fact, future studies will have to show whether the IASD may even be beneficial in selected patient populations by left atrial volume and pressure relief.


  • Open Access

    Drug Coated Balloon-Only Strategy in De Novo Lesions of Large Coronary Vessels

    by Mark Rosenberg, Matthias Waliszewski, Florian Krackhardt, Kenneth Chin, Wan Azman Wan Ahmad, Giuseppe Caramanno, Diego Milazzo, Amin Ariff Nuruddin, Houng Bang Liew, Oteh Maskon, et al.

    Objectives. We analyzed the efficacy of drug coated balloons (DCB) as a stand-alone-therapy in de novo lesions of large coronary arteries. DCBs seem to be an attractive alternative for the stent-free interventional treatment of de novo coronary artery disease (CAD). However, data regarding a DCB-only approach in de novo CAD are currently limited to vessels of small caliber. Methods. By means of propensity score (PS) matching 234 individuals with de novo CAD were identified with similar demographic characteristics. This patient population was stratified in a 1:1 fashion according to a reference vessel diameter cut-off of 2.75 mm in small and large vessel disease. The primary endpoint was the rate of clinically driven target lesion revascularization (TLR) at 9 months. Results. Patients with small vessel disease had an average reference diameter of 2.45 ± 0.23 mm, while the large vessel group averaged 3.16 ± 0.27 mm. Regarding 9-month major adverse cardiac event (MACE), 5.7% of the patients with small and 6.1% of the patients with large vessels had MACE (p=0.903). Analysis of the individual MACE components revealed a TLR rate of 3.8% in small and 1.0% in large vessels (p=0.200). Of note, no thrombotic events in the DCB treated coronary segments occurred in either group during the 9-month follow-up. Conclusions. Our data demonstrate for the first time that DCB-only PCI of de novo lesions in large coronary arteries (>2.75 mm) is safe and as effective. Interventional treatment for CAD without permanent or temporary scaffolding, demonstrated a similar efficacy for large and small vessels.


  • Prospective, large‐scale multicenter trial for the use of drug‐coated balloons in coronary lesions: The DCB‐only All‐Comers Registry

    by Mark Rosenberg, Matthias Waliszewski, Kenneth Chin, Wan Azman Wan Ahmad, Giuseppe Caramanno, Diego Milazzo, Amin Ariff Nuruddin, Houng Bang Liew, Oteh Maskon, Pierre Aubry, et al.

    Objectives: This prospective, observational all‐comers registry assessed the safety and efficacy of a Drug Coated Balloon‐only strategy (DCB‐only) in patients with coronary lesions.Background: Data regarding the performance of a DCB‐only approach, especially in patients with previously untreated de‐novo coronary artery disease (CAD), are still limited.Methods: This study was conducted as an international, multicenter registry primarily enrolling patients with de‐novo CAD. However, it was also possible to include patients with in‐stent restenosis (ISR). The primary endpoint was the rate of clinically driven target lesion revascularization (TLR) after 9 months.Results: A total of 1,025 patients with a mean age of 64.0 ± 11.2 years were enrolled. The majority of treated lesions were de‐novo (66.9%), followed by drug‐eluting‐stent ISR (DES‐ISR; 22.6%) and bare‐metal‐stent ISR (BMS‐ISR; 10.5%). The TLR rate was lower in the de‐novo group (2.3%) when compared to BMS‐ (2.9%) and DES‐ISR (5.8%) (P = 0.049). Regarding MACE, there was a trend toward fewer events in the de‐novo group (5.6%) than in the BMS‐ (7.8%) and DES‐ISR cohort (9.6%) (P = 0.131). Subgroup analyses revealed that lesion type (95% CI 1.127–6.587); P = 0.026) and additional stent implantation (95% CI 0.054–0.464; P = 0.001) were associated with higher TLR rates.Conclusions: Our results show that DCB‐only angioplasty of de‐novo coronary lesions is associated with low MACE and TLR rates. Thus, DCBs appear to be an attractive alternative for the interventional, stentless treatment of suitable de‐novo coronary lesions.


  • Open Access

    Coculture with hematopoietic stem cells protects cardiomyocytes against apoptosis via paracrine activation of AKT

    by Mark Rosenberg, Matthias Lutz, Constantin Kühl, Rainer Will, Volker Eckstein, Jutta Krebs, Hugo A Katus, Norbert Frey

    Background: Previous experimental studies concluded that stem cells (SC) may exert their beneficial effects on the ischemic heart by paracrine activation of antiapoptotic pathways. In order to identify potential cardioprotective mediators, we performed a systematic analysis of the differential gene expression of hematopoietic SC after coculture with cardiomyocytes (CM). Methods: After 48 h of coculture with neonatal rat ventricular CM (NRVCM), two consecutive cell sorting steps generated a highly purified population of conditioned murine hematopoietic SC (>99%). Next, a genome-wide microarray analysis of cocultured vs. monocultured hematopoietic SC derived from three independent experiments was performed. The analysis of differentially expressed genes was focused on products that are secretable and/or membrane-bound and potentially involved in antiapoptotic signalling. Results: We found CCL-12, Macrophage Inhibitory Factor, Fibronectin and connexin 40 significantly upregulated in our coculture model. An ELISA of cell culture supernatants was performed to confirm secretion of candidate genes and showed that coculture supernatants revealed markedly higher CCL-12 concentrations. Moreover, we stimulated NRVCM with concentrated coculture supernatants which resulted in a significant reduction of apoptosis compared to monoculture-derived supernatant. Mechanistically, NRVCMs stimulated with coculture supernatants showed a higher level of AKT-phosphorylation, consistent with enhanced antiapoptotic signaling. Conclusion: In summary, our results show that the interaction between hematopoietic SC and NRVCM led to a modified gene expression and induction of antiapoptotic pathways. These findings may thus at least in part explain the cardioprotective effects of hematopoietic SC.


  • Alkoholische Kardiomyopathie

    by M. Rosenberg, N. Frey